Price	$33	$53	$72
Package	2mg	5mg	10mg

Product Details

Product Name: SRT 1720	CAS No.: 925434-55-5
Purity: 99.7%	Supply Ability: 10g
Release date: 2024/11/19

Product Introduction

Bioactivity

Name	SRT 1720
Description	SRT 1720 is a selective activator of human SIRT1 (EC1.5: 0.16 μM) and exhibits more than 230-fold lower potency for SIRT2 and SIRT3.
Animal Research	Nine-week-old C57BL/6 male mice are fed a high-fat diet (60% calories from fat) until their mean body weight reaches approximately 40 g. The mice are then divided into test groups (6-10 per group). SRT1460 (100 mg/kg), SRT1720 (100 mg/kg), SRT501 (500 mg/kg) and rosiglitazone (5 mg/kg) are administered once daily via oral gavage. The vehicle used is 2% HPMC + 0.2% DOSS. Individual mouse body weights are measured twice weekly. At 2, 4, 6, 8 and 10 weeks of dosing a fed blood glucose measurement are taken and after 5 weeks of treatment, an IPGTT is conducted on all mice from each of the groups. After 10 weeks of treatment, an ITT is conducted. Statistical analysis is completed using the JMP program. Data are analyzed by a one way ANOVA with a comparison to control using a Dunnett's Test. A p-value < 0.05 indicates a significant difference between groups.
In vitro	The maximum activation ratio of SRT1720 versus the closest sirtuin homologs, SIRT2 (EC1.5 = 37 μM) and SIRT3 (EC1.5 > 300 μM) is up to 781%. SRT1720 binds to the SIRT1 enzyme-peptide substrate complex at an allosteric site amino-terminal to the catalytic domain and lower the Michaelis constant for acetylated substrates. Higher concentrations of SRT1720 (15 μM) induces a modest (10-20%) decrease in normal cell viability. SRT1720 also significantly inhibits VEGF-dependent MM cell migration [1].
In vivo	SRT 1720 (10, 30, 100 mg/kg, p.o.) significantly reduces hyperinsulinemia after 4 weeks, partially normalizing insulin levels akin to rosiglitazone treatment, reduces fasting blood glucose to near normal levels in Lepob/ob mice[1], protects against diet-induced obesity in mice by modulating metabolic adaptation through SIRT1 targets such as PGC1α and FOXO1[2], and during emphysema development (50-100 mg/kg, p.o.), attenuates elastase-induced airspace enlargement and lung function impairment, and reduces arterial oxygen saturation in WT mice[3].
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
Solubility Information	DMSO : 1 mg/mL
Keywords	inhibit \| Inhibitor \| SRT1720 \| SRT-1720 \| Sirtuin \| Autophagy \| SRT 1720
Inhibitors Related	Stavudine \| Xylitol \| Myricetin \| Sodium 4-phenylbutyrate \| Hydroxychloroquine \| Guanidine hydrochloride \| Taurine \| Curcumin \| Oxyresveratrol \| Paeonol \| Naringin \| Gefitinib
Related Compound Libraries	Histone Modification Compound Library \| Bioactive Compound Library \| Epigenetics Compound Library \| Anti-Diabetic Compound Library \| NO PAINS Compound Library \| Mitochondria-Targeted Compound Library \| Anti-Aging Compound Library \| Bioactive Compounds Library Max \| Anti-Cancer Compound Library \| Anti-Cancer Active Compound Library

Company Profile Introduction

Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers. TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.

Recommended supplier

Product name	Price		Suppliers	Update time
SRT 1720 dihydrochloride	$78.00/2mg	VIP3Y	TargetMol Chemicals Inc.	2024-11-19
GRL-1720	$1980.00/50mg	VIP1Y	TargetMol Chemicals Inc.	2024-10-28
N-[2-[3-(1-Piperazinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]-2-quinoxalinecarboxamide	$7.00/1KG	VIP5Y	Career Henan Chemical Co	2020-02-18

SRT 1720 NEW

Product Details

Product Introduction

Bioactivity

Company Profile Introduction

You may like

Recommended supplier

TargetMol Chemicals Inc.

Min. Order:
Supply Ability:	10g
Update Time:	2024-11-19